Trial Information
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed after Treatment with Osimertinib (Acclaim-1 Trial)
Sponsor: Genprex, Inc.
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
